. $150 million for U.S. rights to sell Lilly's molecule tadalafil as a treatment for pulmonary arterial hypertension (PAH), a rare blood vessel disorder. Lilly already markets tadalafil to treat erectile dysfunction under the brand name Cialis, and it has filed for regulatory approval to use the drug to treat PAH in North America, Japan, and Europe.
by Lisa M. Jarvis |
November 24, 2008